WallStreetZenWallStreetZen

NASDAQ: CMMB
Chemomab Therapeutics Ltd Stock

$1.11-0.03 (-2.63%)
Updated Jul 12, 2024
CMMB Price
$1.11
Fair Value Price
$0.76
Market Cap
$15.77M
52 Week Low
$0.42
52 Week High
$1.46
P/E
-0.71x
P/B
1.18x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$19.34M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.35
Operating Cash Flow
N/A
Beta
1.16
Next Earnings
Aug 12, 2024
Ex-Dividend
N/A
Next Dividend
N/A

CMMB Overview

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CMMB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CMMB ($1.11) is overvalued by 45.17% relative to our estimate of its Fair Value price of $0.76 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CMMB ($1.11) is not significantly undervalued (45.17%) relative to our estimate of its Fair Value price of $0.76 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CMMB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CMMB due diligence checks available for Premium users.

Be the first to know about important CMMB news, forecast changes, insider trades & much more!

CMMB News

Valuation

CMMB fair value

Fair Value of CMMB stock based on Discounted Cash Flow (DCF)
Price
$1.11
Fair Value
$0.76
Overvalued by
45.30%
CMMB ($1.11) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CMMB ($1.11) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CMMB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CMMB price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.71x
Industry
-12.81x
Market
32.2x

CMMB price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.18x
Industry
6.45x
CMMB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CMMB's financial health

Profit margin

Revenue
$0.0
Net Income
-$3.9M
Profit Margin
0%

Assets to liabilities

Assets
$18.0M
Liabilities
$4.7M
Debt to equity
0.35
CMMB's short-term assets ($16.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CMMB's short-term assets ($16.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CMMB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A

CMMB vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CMMB$15.77M-2.72%-0.71x1.18x
NRSN$15.53M-1.94%-1.36x-8.83x
KTRA$16.04M+6.23%-0.07x2.71x
BCTX$16.16M-3.18%-2.39x-2.71x
GLTO$14.78M+5.83%-0.48x0.52x

Chemomab Therapeutics Stock FAQ

What is Chemomab Therapeutics's quote symbol?

(NASDAQ: CMMB) Chemomab Therapeutics trades on the NASDAQ under the ticker symbol CMMB. Chemomab Therapeutics stock quotes can also be displayed as NASDAQ: CMMB.

If you're new to stock investing, here's how to buy Chemomab Therapeutics stock.

What is the 52 week high and low for Chemomab Therapeutics (NASDAQ: CMMB)?

(NASDAQ: CMMB) Chemomab Therapeutics's 52-week high was $1.46, and its 52-week low was $0.42. It is currently -24.04% from its 52-week high and 164.05% from its 52-week low.

How much is Chemomab Therapeutics stock worth today?

(NASDAQ: CMMB) Chemomab Therapeutics currently has 284,379,960 outstanding shares. With Chemomab Therapeutics stock trading at $1.11 per share, the total value of Chemomab Therapeutics stock (market capitalization) is $15.77M.

Chemomab Therapeutics stock was originally listed at a price of $172.80 in Feb 12, 2019. If you had invested in Chemomab Therapeutics stock at $172.80, your return over the last 5 years would have been -99.36%, for an annualized return of -63.57% (not including any dividends or dividend reinvestments).

How much is Chemomab Therapeutics's stock price per share?

(NASDAQ: CMMB) Chemomab Therapeutics stock price per share is $1.11 today (as of Jul 12, 2024).

What is Chemomab Therapeutics's Market Cap?

(NASDAQ: CMMB) Chemomab Therapeutics's market cap is $15.77M, as of Jul 15, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Chemomab Therapeutics's market cap is calculated by multiplying CMMB's current stock price of $1.11 by CMMB's total outstanding shares of 284,379,960.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.